FDA rejects emergency use authorization for fluvoxamine: Ineffective in treating COVID-19
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
FDA rejects emergency use authorization for fluvoxamine: Ineffective in treating COVID-19
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
FDA rejects emergency use authorization for fluvoxamine: Ineffective in treating COVID-19.
When the U.S. Food and Drug Administration (FDA) rejected an antidepressant as a treatment for COVID-19 on Monday, it also released a 27-page memo explaining exactly why this drug wasn’t believed to be effective.
It was an unusual move for the agency, which typically quietly refuses drugs without so much public documentation.
The antidepressant fluvoxamine is an inexpensive generic drug that has been used for decades. Research has shown that the drug can also block inflammation in the body.
As a result, some researchers hope it can help prevent severe symptoms in COVID-19 patients, some of whom have to deal with inflammation due to an overactive immune system.
Some small and preliminary studies suggest it may be able to reduce the risk of severe illness in people with COVID-19. But these studies were not enough to convince the FDA. In its memo, the agency said studies submitted in support of the drug did not adequately show that it could provide “clinically meaningful results” — reducing hospitalizations and deaths.
The main study, known as the Together trial, found that the drug reduced the likelihood that patients were in the emergency room for more than six hours. The FDA does not consider this metric important.
When the FDA rejects a drug, it’s uncommon to get this type of window into its decision-making process.
In most cases, the decision is in the hands of the pharmaceutical company that makes the drug, and it is kept secret. Research shows that these companies tend not to publish the results of rejections, and when they do, they don’t publicly explain why.
People do want to know, though: A survey of U.S. adults released in February found that nearly 90 percent said they wanted to make public information about a drug that wasn’t approved.
It’s worth noting that the use of fluvoxamine as a treatment for COVID-19 wasn’t submitted to the FDA by a pharmaceutical company — a group of doctors asked the agency to approve it. Because it is an ancient generic drug, no pharmaceutical company will profit from an expensive regulatory process.
FDA rejects emergency use authorization for fluvoxamine: Ineffective in treating COVID-19
(source:internet, reference only)
Disclaimer of medicaltrend.org
